EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSMZEG00005016364
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSMZEG00005007204
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha

Ensembl ID : ENSMZEG00005020832
Gene Symbol: LOC101467375
3 Cross references
244 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B

Ensembl ID : ENSMZEG00005011449
Gene Symbol: LOC101474809
3 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSMZEG00005003079
Gene Symbol: SCN4A
3 Cross references
190 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSMZEG00005007579
Gene Symbol: SCN8A
4 Cross references
216 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSMZEG00005000344
Gene Symbol: SCN8A
3 Cross references
215 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1

Ensembl ID : ENSMZEG00005025927
Gene Symbol: LOC101472311
3 Cross references
205 Possible Orthologues:

Sodium-Dependent Serotonin Transporter

Ensembl ID : ENSMZEG00005006594
Gene Symbol: LOC101466776
3 Cross references
201 Possible Orthologues:

Sodium/glucose Cotransporter 1

Ensembl ID : ENSMZEG00005018037
Gene Symbol: LOC101464156
3 Cross references
242 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSMZEG00005018051
Gene Symbol: LOC101467218
3 Cross references
241 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSMZEG00005018047
Gene Symbol: LOC101467512
3 Cross references
241 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).